VitaNova Life Sciences (VNOV) Accumulated Expenses (2017 - 2026)

VitaNova Life Sciences has disclosed Accumulated Expenses across 9 years of filings, most recently posting $79903.0 for Q3 2026.

• Accumulated Expenses for Q3 2026 came in at $79903.0, changed N/A year-over-year; the trailing twelve-month figure through Jul 2026 was $79903.0 (changed N/A YoY), and the FY2026 annual result was $78959.0, up 29.69% from the prior year.
• Accumulated Expenses for Q3 2026 stood at $79903.0, up from $78959.0 in the prior quarter.
• Across five years, Accumulated Expenses topped out at $81951.0 in Q1 2026 and bottomed at $38391.0 in Q1 2022.
• Average Accumulated Expenses over 5 years is $57943.7, with a median of $51275.0 recorded in 2023.
• The widest annual swing landed in 2022, when Accumulated Expenses soared 61.02%; it then retreated 4.94% in 2023.
• Year by year, Accumulated Expenses stood at $53343.0 in 2022, then slipped by 4.94% to $50707.0 in 2023, then slipped by 1.0% to $50202.0 in 2024, then soared by 36.87% to $68713.0 in 2025, then grew by 16.29% to $79903.0 in 2026.
• The last three Accumulated Expenses figures came in at $79903.0 (Q3 2026), $78959.0 (Q2 2026), and $81951.0 (Q1 2026), per Business Quant data.